Breaking the Diagnostic Bottleneck: Tackling a $635B Liver Crisis

TARRYTOWN, NY – September 21, 2026 — When a revolutionary therapeutic hits the market, the greatest barrier to commercial success isn't always payer pushback or physician skepticism. Often, the primary hurdle is simply finding the patients. This is the exact commercial bottleneck currently defining the multi-billion-dollar race to treat metabolic dysfunction-associated steatohepatitis (MASH), a silent epidemic that has rapidly become a focal point for the biopharmaceutical industry.

In a move that signals a structural shift in how complex metabolic diseases will be commercialized, Siemens Healthineers and Novo Nordisk announced a strategic collaboration today. The partnership pairs one of the world's leading in vitro diagnostic companies with a cardiometabolic pharmaceutical giant to streamline the detection and management of metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, MASH.

By standardizing non-invasive diagnostic pathways, the two companies are attempting to solve a massive funnel problem: how to identify the millions of undiagnosed patients who are eligible for newly approved therapies before they suffer irreversible liver damage.

The Commercial Funnel and a $635 Billion Epidemic

To understand the strategic logic behind this partnership, one must look at the sheer scale of the metabolic liver disease crisis. MASLD affects nearly a quarter of all adults in the United States. Driven by rising rates of obesity and type 2 diabetes, the condition has quietly overtaken hepatitis C and alcohol-associated liver disease to become the leading indication for liver transplantation among women.

Despite this high prevalence, the disease progresses silently. Patients rarely exhibit symptoms until the liver reaches advanced fibrosis or cirrhosis. Health economists project that the U.S. healthcare costs associated with managing end-stage liver disease—including decompensated cirrhosis, cardiovascular events, and liver failure—will surpass $635 billion by the end of the decade.

For pharmaceutical companies like Novo Nordisk, which recently secured accelerated FDA approval for semaglutide 2.4 mg (Wegovy) to treat noncirrhotic MASH, the market opportunity is staggering. However, therapeutics like Wegovy and Madrigal Pharmaceuticals' Rezdiffra are strictly indicated for patients with moderate to advanced fibrosis (stages F2 to F3).

Out of the estimated 15 to 20 million U.S. adults with MASLD, only 3 to 5 million have progressed to this specific F2-F3 window. Finding these specific patients buried within millions of routine primary care visits is virtually impossible without a scalable, accessible diagnostic infrastructure.

Ending the Biopsy Era: Diagnostics as a Market Maker

Historically, the gold standard for diagnosing liver fibrosis has been the liver biopsy. For half a century, proving a patient had MASH required a specialist to insert a needle into the liver—an invasive, painful procedure carrying risks of hemorrhage and hospitalization. Furthermore, biopsies are notoriously prone to sampling errors, analyzing only about 1/50,000th of the organ's volume, which leads to high inter-observer variability among pathologists.

While non-invasive imaging technologies like vibration-controlled transient elastography (VCTE, commonly known as FibroScan) have modernized the field, they come with their own commercial limitations. These specialized ultrasound machines require capital investments of up to $50,000 per unit and are typically siloed in gastroenterology or hepatology clinics. More importantly, acoustic wave attenuation struggles through thick chest walls, resulting in a 5% to 15% technical failure rate in patients with severe obesity (a BMI of 35 or higher)—the exact demographic most at risk for MASH.

This is where Siemens Healthineers provides the missing commercial link. The company’s Enhanced Liver Fibrosis (ELF) test is currently the first and only blood test authorized in the United States to help clinicians assess the risk of disease progression in patients with advanced fibrosis due to MASH.

The ELF test measures three direct circulating biomarkers of extracellular matrix turnover in human serum: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1). Because it is an analyte-based serum assay, the ELF test's performance is entirely independent of a patient's body mass index or adipose tissue deposition.

"Too often, liver health flies under the radar," said Michele Zwickl, head of Laboratory Solutions for Siemens Healthineers North America. "People deserve the same level of awareness as for other major diseases, creating a better opportunity to intervene before serious complications develop."

By shifting the point of detection from the specialist's operating suite to a standard peripheral venipuncture at national reference laboratories like Quest Diagnostics and Labcorp, the ELF test effectively democratizes MASH screening.

The Economics of Triage and Payer Access

From a commercialization standpoint, diagnostic availability is only half the battle; payer reimbursement is the other. The American Medical Association assigned the ELF test a Category 1 CPT code (81517), and Medicare generally reimburses the assay between $125 and $180. However, commercial insurers have historically applied prior-authorization controls to multianalyte panels, creating friction for primary care physicians who are already battling severe time constraints.

To eliminate this financial barrier and accelerate therapeutic uptake, Novo Nordisk has strategically deployed a market-making maneuver: the NovoDETECT program. Through this initiative, the pharmaceutical manufacturer provides support to cover the out-of-pocket costs—such as copayments and deductibles—incurred by commercially insured patients for non-invasive liver tests, including the Siemens ELF test.

By subsidizing the diagnostic step, Novo Nordisk removes payer denial as a deterrent for primary care doctors. This facilitates a seamless reflex testing pathway. In practice, a physician can order a routine metabolic panel, calculate a basic FIB-4 index using standard liver enzymes and age, and if the patient scores in a high-risk category, automatically reflex to the ELF blood test. If the ELF score falls between 9.80 and 11.29, the patient is flagged as a prime candidate for therapeutic intervention, completely bypassing the hepatology referral bottleneck.

Independent health economists note that this two-tier triage strategy costs less than $200 per patient. Compared to the $60,000 to $150,000 annual cost of managing end-stage liver disease, or the $800,000 lifetime cost of a liver transplant, early non-invasive blood testing presents an undeniable value proposition to the broader healthcare system.

A Blueprint for Future Blockbusters

The convergence of high-throughput diagnostics and targeted metabolic therapeutics represents a new frontier in drug commercialization. Novo Nordisk’s ESSENCE Phase 3 trial data already demonstrated that semaglutide significantly improves liver fibrosis and resolves steatohepatitis without worsening fibrosis. Notably, the trial also showed profound reductions in Siemens ELF scores among treated patients, proving that these non-invasive blood markers correspond directly with histologic healing.

As competitors like Eli Lilly and Akero Therapeutics advance their own MASH pipelines, the ability to effortlessly identify and monitor patients will become a primary competitive advantage. A blockbuster drug cannot generate revenue if it sits on the shelf waiting for a liver biopsy to be scheduled.

"Earlier triage is one of the most important opportunities to improve the future of MASH care," said Michelle Long, senior international medical director for MASH at Novo. "Our collaboration recognizes that patients, clinicians, laboratories, health systems, and industry partners all have a role to play in creating a more effective pathway for liver disease assessment and management."

For industry analysts and healthcare investors, the Siemens-Novo alliance is more than a joint public relations campaign; it is a meticulously engineered commercial pipeline. By tearing down the diagnostic barriers that have historically bottlenecked liver care, these companies are not just preparing the market for a new wave of therapeutics—they are actively creating it.